Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Sanofi is a global healthcare company that researches, makes, and sells medicines and vaccines.
Sanofi is one of the world's biggest drugmakers, a company that turns chemistry, biology, and years of careful testing into medicines and vaccines that doctors prescribe to millions of people. Its products range from everyday over-the-counter remedies like allergy pills and cough syrup to complex prescription drugs for conditions such as asthma, multiple sclerosis, and rare diseases. It also makes a huge share of the world's flu vaccines and sells shots that protect children against diseases like polio and whooping cough. So the people who pay Sanofi are mostly insurers, governments, and hospitals rather than patients directly.
The business splits into three main pieces. The biggest is a unit called Specialty Care, which sells expensive, hard-to-make medicines for conditions like rare blood disorders and immune diseases — the kind of drugs that cost tens of thousands of dollars a year and take years to develop. The second is General Medicines, the more everyday branded drugs and over-the-counter products that bring in steady cash. The third is Vaccines, where Sanofi is one of the largest players on the planet. There's also a consumer health division selling things like vitamins and pain relievers, and a separate company called Opella was carved out to hold much of that business. What makes a drug company so powerful is the patent system — a new medicine is protected from copycats for around 20 years, letting the maker charge high prices to recoup research costs. The catch is what happens when the patent clock runs out and cheaper generic versions flood in, a looming "patent cliff" that Sanofi and every big drugmaker must constantly outrun by inventing new medicines. Sanofi's biggest bet here is a drug called Dupixent, used for severe eczema and asthma, which has become a monster seller; its growth has been central to the company's story. Sanofi spends heavily on research, and it has been striking deals to buy promising biotech compounds rather than build everything in-house.
For years Sanofi was a bit of a disappointing performer, with its shares lagging rivals, so the company launched a turnaround under a new management team. That effort included buying a company called Translate Bio for its messenger RNA technology, betting on the next generation of vaccines and medicines. It also announced plans to spin off the consumer health business, focusing the company more tightly on innovative prescription drugs and vaccines. All of this is set against a hard truth of the industry: developing a drug is a long, expensive lottery, most candidates fail, and success can hinge on a single molecule. Sanofi's job is to keep winning enough of that lottery to stay ahead of the day its bestsellers lose protection.
Saved answer · last researched 23 Oct 2026